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Abstract
Diffuse intrinsic pontine glioma (DIPG), a rare, often fatal childhood brain tumor, remains a major 
therapeutic challenge. In 2012, investigators, funded by the DIPG Collaborative (a philanthropic 
partnership among 29 private foundations), launched the International DIPG Registry (IDIPGR) to 
advance understanding of DIPG. Comprised of comprehensive de identified but linked clinical, 
imaging, histopathological, and genomic repositories, the IDIPGR uses standardized case report 
forms for uniform data collection; serial imaging and histopathology are centrally reviewed by 
IDIPGR neuro-radiologists and neuro-pathologists, respectively. Tissue and genomic data, and cell 
cultures derived from autopsies coordinated by the IDIPGR are available to investigators for 
studies approved by the Scientific Advisory Committee. From April 2012 to December 2016, 670 
patients diagnosed with DIPG have been enrolled from 55 participating institutions in the US, 
Canada, Australia and New Zealand. The radiology repository contains 3558 studies from 448 
patients. The pathology repository contains tissue on 81 patients with another 98 samples available 
for submission. Fresh DIPG tissue from seven autopsies has been sent to investigators to develop 
primary cell cultures. The bioinformaticsrepository contains next-generation sequencing data on 
66 tumors. Nine projects using data/tissue from the IDIPGR by 13 principle investigators from 
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around the world are now underway. The IDIPGR, a successful alliance among philanthropic 
agencies and investigators, has developed and maintained a highly collaborative, hypothesis-driven 
research infrastructure for interdisciplinary and translational projects in DIPG to improve 
diagnosis, response assessment, treatment and outcome for patients
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Background
Diffuse intrinsic pontine glioma (DIPG) is an aggressive childhood brainstem tumor with a 
dismal prognosis. [1, 2] The diagnosis of DIPG has, hitherto, been based on imaging and 
clinical findings. The reluctance to conduct brainstem biopsies, a paradigm which has 
recently been challenged, [3–6] long hindered understanding of this fatal disease. Radiation 
therapy prolongs survival by only 2–3 months and remains the standard of care,[7] while 
chemotherapy has proven ineffective [8].
In 2012, next-generation sequencing studies using autopsy and some biopsy tissue 
elucidated the genomic landscape of DIPG [9, 10]. Despite these discoveries, DIPG research 
remains challenging, due to the tumor’s relative rarity, the limited power of single-institution 
or small-scale studies, presence of inter- and intra-tumoral heterogeneity, and a lack of 
understanding of mechanisms of therapy resistance [11, 12].
In 2011, physicians, scientists, and patient advocacy groups met at the first International 
DIPG Symposium, and advocated for the establishment of a focused international effort to 
develop uniform criteria for diagnosis, classification, disease assessment, and to study DIPG 
biology and therapeutic strategies through the development of in vitro and in vivo models. In 
2012, with financial support from the DIPG Collaborative, a philanthropic partnership which 
now includes 29 private foundations, and international investigators banded together to 
establish the International DIPG Registry (IDIPGR) and a parallel European SIOPE 
Registry. The IDIPGR continues to expand and maintains a highly-collaborative, hypothesis-
driven research infrastructure to support a wide spectrum of interdisciplinary and 
translational projects in DIPG. Here, we report the logistical challenges, pitfalls, and 
successes of developing this registry, which we hope will serve as a model for other orphan 
disease registries.
Methods
Structure of the DIPG registry
The IDIPGR consists of the Operations Center (OC), a Steering Committee (SC), Scientific 
Advisory Committee (SAC), Research Ethics Panel, Quality Assurance Group, and 
collaborating institutions. An organizational chart is provided in Fig. 1.
Cincinnati Children’s Hospital Medical Center (CCHMC) is the Operations Center and 
repository for all clinical and neuroimaging data and pathology specimens from 
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collaborating institutions. Tissue from Canada is stored in a separate biobank at The 
Hospital for Sick Children.
The SC serves as the governing board, providing oversight of the IDIPGR. SC consists of 
experts in the field of DIPG, and one patient/family representative. Non-voting members 
include two registry staff members: the IDIPGR project coordinator and the regulatory and 
ethics officer. The SAC consists of senior basic, translational and clinical experts in DIPG 
research, including two external reviewers, and is responsible for evaluating and prioritizing 
submitted research proposals. The Registry’s policies and detailed organizational 
information are outlined in the DIPG Registry and Repository constitution. The SC meets 
semi-annually by teleconference or in-person. Biannually, an in-person meeting of the SC 
and SAC is conducted.
Registry website (http://www.dipgregistry.org)
A website, http://www.dipgregistry.org, representing the International and SIOPE DIPG 
Registries, serves as a direct link between families/medical professionals and registry 
personnel, providing a list of registry-affiliated oncologists around the world, clinical trials 
and research updates, investigator profiles and educational information about DIPG, 
palliative care and autopsy. The website also facilitates consultations or self-referrals to the 
registries. Information on the website is updated monthly by the registry coordinators and 
the Principle Investigator to reflect the most up-to-date information available.
Recruitment and data collection
There are two principal mechanisms for identification and recruitment of participants (a) 
self-referral by patients and their families via the DIPG Registry website or (b) procurement 
of deceased patient records from participating institutions, after Institutional Review Board 
(IRB) approval or non-humansubjects determination. All patients, regardless of age, with an 
institutional diagnosis of DIPG are eligible for enrolment in the International DIPG Registry.
Self-referral—Prospective patients and their families may self-refer by contacting the 
IDIPGR office directly at http://www.dipgregistry.org or by phone. Physicians and medical 
staff may also provide prospective patients with the IDIPGR brochure. Once self-referral is 
made, registry staff contact the patient or parent/guardian (for minor patients) to obtain 
consent for registry participation. When possible, written assent to participate is also 
obtained from patients ≥11 years old. Once written consent has been obtained, registry staff 
work directly with the treating medical team to collect information, imaging, and tissue 
samples, if available.
Parents/legal guardians of deceased patients may also self-refer to the IDIPGR and grant 
registry personnel access to the decedent’s medical information by signing a HIPAA release 
form.
Institutional referral—Each collaborating institution is responsible for providing source 
documentation for registry personnel to abstract data from medical records of their DIPG 
patients. The IDIPGR coordinator works with a designee from each collaborating institution 
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to obtain source documentation, including medical records, radiographic imaging on CD-
ROM, available pathological material. Data are abstracted from the medical record by the 
IDIPGR coordinator, who is solely responsible for completing case report forms (CRF) and 
entering into the Registry database. If release of individually identifiable medical records of 
deceased patients is not permissible from a collaborating institution, the CRFs may be 
completed on site using a data abstraction guide developed to ensure uniform interpretations 
and collection of variables/data points. Radiographic images submitted on CD-ROM are de-
identified, uploaded, and stored in the research picture archiving and communication 
systems (PACS) system housed at CCHMC. All paraffin blocks/slides or frozen tissue for 
central pathology review and/or future research are de-identified and sent to CCHMC, or 
The Hospital for Sick Children (HSC) for Canadian sites.
Collaborating institutions can inform prospective, living patients about the IDIPGR, either 
verbally or by providing IRB-approved brochures. Interested patients or families may then 
self-refer to the IDIPGR for enrolment. For international sites, local staff may obtain 
informed consent per institutional and country policies using site-specific consent forms 
approved by their ethics committee based on the IRB-approved consent template provided 
by the IDIPGR.
Data inclusion moratorium—Investigators at each institution may elect to place a 1-year 
moratorium on inclusion of their data (clinical, imaging, pathology/tissue) as part of any 
research or publications from the IDIPGR. The moratorium begins when the first patient 
records are accessed. The collaborating institution may request an extension of the 
moratorium if needed for projected publication of institutional data donated to the registry.
Regulatory strategies
Institutions in the United States—The IRB approval for the IDIPGR is maintained at 
the CCHMC operations center. According to HIPAA regulation 45 CFR 164.512, the request 
for and release of decedent personal health information (PHI) for research purposes is 
permitted and HIPAA requirements are fulfilled as part of a decedent PHI request form 
(available on request). All PHI received by the IDIPGR is coded. The IDIPGR research 
personnel function as the honest brokers ensuring that no identifying information is released 
to researchers. Many collaborating institutions have consulted with their IRB and acted in 
accordance with institutional policy. Some of the submissions to IRBs have included the 
decedent request form and brief explanation of use of PHI through completion of their IRB 
application. Most IRBs have granted a non-human subjects research determination and grant 
HIPAA waivers. Since the informed consent is obtained by Registry staff, institutions should 
not need to obtain full IRB approval.
International institutions—For international sites, local staff may obtain informed 
consent of living participants according to institutional and country policies using a site-
specific consent form approved by their Research Ethics Board. Privacy laws do not 
typically permit release of PHI, requiring most international sites to submit data on CRFs 
and maintain source documents, including consent forms, on-site.
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Protocols and procedures
Clinical database—Demographic, clinical, treatment, and outcome data are abstracted 
from existing clinical records, pathology and imaging reports by the two IDIPGR 
coordinators using standardized case report forms (CRFs). Clinical CRFs have been 
developed in conjunction with investigators from the SIOPE DIPG Registry for collection of 
identical data that would enable facile collaboration. Data are coded and stored in Oncore, a 
clinical trials management software system. Abstracted data elements include: 
demographics, diagnosis, date of diagnosis, imaging, signs and symptoms and physical 
exam at diagnosis, treatment, response evaluations, central pathology review characteristics, 
central imaging review characteristics, and molecular profile. All source documentation is 
maintained at the operations center in patient binders for access for future studies and 
quality assurance. Annually, members of the oncology quality assurance team at CCHMC 
review 10% of all patient data for completion and accuracy and provide formal reports 
regarding their findings.
Imaging repository—All available imaging on each enrolled subject is submitted to the 
central imaging repository at the OC on CD, and loaded onto a dedicated, research-only, 
picture archiving and communication system (PACS). Data are reviewed prior to placement 
in the research PACS to ensure all patient identifiers are removed from images, and a study 
ID generated, linkable to the subject identity only by DIPG Registry staff.
MR imaging is reviewed by the study primary neuroradiologists (BVJ, JLL) at diagnosis, 
post-radiation, best response to each therapy, and at the time of progression with each 
therapeutic intervention. An international central neuroimaging review panel is available as 
needed to define/ cross validate evaluation parameters. All cases are reviewed by both 
primary neuroradiologists and consensus opinions utilized in cases in which there is 
disagreement. The primary goal of central review is to confirm the imaging diagnosis of 
DIPG, provide measurements of tumor extent, and basic descriptive assessments of imaging 
appearance. Each case is evaluated and classified as: (1) typical DIPG imaging appearance, 
(2) some atypical features, but likely DIPG, and (3) unlikely DIPG, other diagnosis 
suspected. A tumor is considered a typical DIPG if it arises from the pons, exhibits a diffuse 
pattern of involvement, and involves ≥50% of the pons at diagnosis. Each case classified as 
unlikely DIPG by consensus opinion of both neuroradiologists will be designated as such in 
the IDIPGR database and excluded from analyses. Imaging features suggestive of an 
alternative diagnosis may include: tumor not arising from the pons (medulla or midbrain 
origin), a primarily focal exophytic morphology, very sharply defined margins, or marked 
diffusion restriction of the majority of the lesion. Cases in which there is secondary 
brainstem involvement by a tumor centered in the thalami, cerebral hemispheres, or 
cerebellar hemispheres are excluded. Only tumors that appear to originate in the brainstem 
are included in the registry. After consensus review, MR imaging data will be entered into 
the registry database for use by approved research studies.
Biospecimen repository—If biopsy or autopsy materials are available, submission is 
requested at the time of enrolment. The Division of Pathology at CCHMC archives and 
digitizes all pathology cases using Biomaterial Tracking and Management Research (BTM). 
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De-identified pathology images and reports are centrally reviewed by the study primary 
neuropathologists at CCHMC (CF) or HSC (CH) in Canada for Canadian patients. Frozen 
specimens originating from referring institutions in Canada are sent to HSC for long-term 
storage. Frozen specimens originating from all other institutions around the world are stored 
at CCHMC.
Genomics repository—Molecular data, including genome-wide DNA copy number, 
karyotyping, expression profiling (mRNA and miRNA), methylation analysis, and DNA or 
RNA sequencing is collated into an International DIPG Bioinformatics Repository. Both 
original raw data and processed files are requested, and can be uploaded along with 
annotation files to a secure ftp site. For autopsy tissue that has been donated to the IDIPGR, 
if molecular/genomics testing have not been conducted or are not available, next generation 
sequencing consisting of whole genome sequencing, RNA sequencing, paid for through 
IDIPGR funds are being conducted by core facilities or commercial vendors and 
deidentified, raw data are then deposited in the genomics repository. Investigators who have 
donated tissue to the IDIPGR can receive raw NGS data generated from specimens 
submitted to the IDIPGR.
Researchers are invited to contribute any relevant data in addition to that which may be 
found in the published literature or databases. Investigators known to have unpublished data 
are approached to contribute pre-publication. Data may be held in this context in a non-
public (password-controlled) area. Data generated from biospecimens contributed to the 
Registry are also incorporated into the repository in a prospective manner.
Sample identifiers are linked to those in the IDIPGR to allow correlation of molecular and 
clinico-pathological variables. The IDIPGR staff maintain the link. The repository is held at 
the genomic data facility in the Bioinformatics Division at CCHMC. By combining these 
data, we intend to generate a comprehensive, accessible database of the molecular profiles of 
DIPG for the academic community.
Results
Current status
The IDIPGR has enrolled 670 patients, from 55 collaborating institutions in the United 
States, Canada, and Australia, and New Zealand with an additional 500 patients committed 
from 25 other sites in these countries, which are at various points in their approval and data 
submission processes. Data have been abstracted on all enrolled patients. A summary of 
available clinical, radiographic, genomics data and biospecimens are summarized in Table 1. 
Currently, 81 tumor specimens are housed in the pathology biorepository with 
approximately 98 more specimens committed for sub-mission on enrolled patients. Next 
Generation Sequencing data from tumor and germline are currently available on 66 patients.
Registry research studies
Nine studies, from various investigators in the US, Canada and Europe have been approved 
by the SAC utilizing registry resources. Several of these studies have external funding, 
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including funding from the DIPG Collaborative. The studies are in various stages of conduct 
and analysis and include:
1. Joint International and SIOP-E DIPG Registry long-term survivor project. To 
describe the clinical, radiographic, pathological and biologic characteristics of 
long-term survivors with DIPG and correlate key variables with outcome.
2. An epidemiological study to determine incidence patterns of DIPG in North 
America. Our Canadian collaborators have presented the Canadian epidemiology 
data and we plan to expand this study to examine incidence of DIPG in other 
countries.
3. External validation of the Survival Prediction Model for Diffuse intrinsic pontine 
glioma. A survival prediction model, developed within a cohort of European 
DIPG patients is being validated using the International DIPG Registry cohort.
4. DIPG: Contemporary Survival Endpoints. A study examining reported survival 
endpoints in order to better define progression and aid the development of 
objective measures for robust clinical trials.
5. Establishment of in vitro and in vivo Models. Fresh tissues from autopsy are 
being shared to establish in vitro and in vivo models for drug screening.
6. Comprehensive Molecular-Based Cross-Species Comparison of DIPG Biology 
examines overlapping genetic alterations between mouse and human DIPG, 
allowing for identification of novel subtype-specific oncogenic pathways.
7. Imaging Phenotype and Survival in DIPG. This proposal seeks to identify 
specific imaging features at baseline that significantly correlate with overall 
survival and assess multi-reader agreement and concordance with imaging 
features of the DIPG registry.
8. DIPG as a complication of Medulloblastoma Therapy. This proposal seeks to 
study the incidence of brainstem glioma as a complication of therapy for 
medulloblastoma.
9. Radiogenomic Evaluation in Diffuse Intrinsic Pontine Glioma.
Consultations, second opinions and education via (http://www.dipgregistry.org)
Since the website launched in April 2012, over 218,000 people have visited the site from 
183 countries. Dipgregistry.org is now an established centralized resource for patients, 
families and physicians around the world in search of up-to-date information regarding 
DIPG including DIPG education, currently open clinical trials, latest literature and research 
developments, access to an international network of oncologists for consultations. To date, 
283 consultations have been provided to patients, families and physicians around the world. 
These consultations are provided by DIPG Registry participating investigators from around 
the world depending on the origin of the consult requests. Since the IDIPGR is housed at 
CCHMC, initial review of consult requests is conducted by Registry Coordinators, IDIPGR 
PI (MF) and triaged accordingly. Consultation by the IDIPGR PI, review of imaging by 
IDIPGR neuroradiologists (JL and BVJ) is provided free of charge to patient.
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Tissue procurement efforts
Recently, greater acceptance of the safety of DIPG biopsy, [3–5, 13] development of 
autopsy-based protocols, [14–16] and next generation sequencing (NGS) efforts have 
advanced our understanding of the molecular basis of DIPG, identifying aberrations such as 
the highly recurrent histone mutations (H3F3A or HIST1H3B/C/I) [9, 10, 17] and ACVR1 
[18–20]. The IDIPGR repository contains tissue specimens on 81 enrolled patients and NGS 
data on 66 enrolled patients. Registry funding supports conduct of comprehensive whole 
genome sequencing, RNA sequencing and 850 K methylation array on all available 
specimens. Spurred on by the explosion of knowledge about this disease through tissue 
donations, many patients and families have contacted the IDIPGR to assist in organizing 
autopsies at participating institutions to donate tissue for research to the Registry. Registry 
staff have organized 24 autopsy donations to the Registry. Tumor specimens from seven 
patients have been sent to registry investigators to establish patient-derived cell culture and 
xenograft models for drug screening and other studies. To date, one cell culture has been 
successfully established.
Funding strategies
One of the major obstacles to establishing and maintaining registries for rare cancers is the 
lack of sustained funding opportunities to support such efforts. The IDIPGR has been 
generously supported by the DIPG Collaborative from 2012 to 2018 for a total of $1.4 
million. The DIPG Collaborative also fully funds SIOPE DIPG Registry. The DIPG 
Collaborative and IDIPGR formed in parallel in 2012, when the need for collaborative 
research and funding became evident. The DIPG Collaborative is comprised of 29 
foundations supporting DIPG research world-wide. The growth of the DIPG Collaborative 
has been vital to sustaining the International DIPG Registry and this relationship remains an 
integral part of maintaining and improving research for this orphan disease.
Discussion
In a rare orphan disease like DIPG, scientific progress and development of effective 
therapies have often been impeded by the lack of large scale, well-annotated, clinico-
radiologic and biologic data available about the disease. The IDIPGR provides the 
infrastructure for acquisition of biological specimens, imaging, and correlative clinical and 
genomics data to facilitate basic and translational research studies in this rare disease. The 
increased availability and centralization of data and specimens from DIPG patients, and the 
effective collaboration among clinical, translational and basic researchers as well as 
philanthropic foundations represent a welcome paradigm shift in DIPG research in which 
data and tumor specimens are no longer rate-limiting resources.
The highly collaborative, international, hypothesisdriven and hypothesis-generating research 
infrastructure of the IDIPGR can support a wide spectrum of interdisciplinary and 
translational research that will be critical to improving diagnosis, classification, response 
assessment and treatment options for this vulnerable population. Centralized, standardized 
and linked pathologic, clinical, genomics and radiological data enable investigators to 
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develop new approaches to DIPG diagnosis, classification and response assessment that will 
inform the development and conduct of future clinical trials.
Tissue acquisition from autopsies on the DIPG Registry has led to critical collaborations 
among basic science and translational investigators to develop primary cell cultures and 
xenografts to support assay development and high throughput screening of novel agents for 
the treatment of DIPG. Keys to these discovery efforts are the ability to integrate analysis of 
relevant genes and pathways and assess potential biomarkers. Comprehensive genomics and 
functional proteomics efforts are already on the way through international collaborations by 
scientists utilizing the IDIPGR infrastructure and biorepository. Promising drugs can then be 
tested in the animal models and cell lines developed from registry tissue and provide the 
rationale for scientifically-sound clinical trials to improve outcome. Dipgregistry.org 
provides a platform to disseminate results and aid recruitment of patients for future studies.
Data requests and research proposals
Data and samples from the registry are available to researchers affiliated with the registry 
and to external researchers world-wide. Research proposals (application available on the 
DIPG registry website) from participating investigators are evaluated by the SAC for 
scientific merit, prioritization, feasibility and appropriate use of resources before approval. If 
approved, de-identified clinical, radiographic, pathologic, genomic data and biological 
specimens may be released to investigators. IDIPGR statistician and bioinformaticians 
perform and provide detailed analyses to the investigators for manuscript preparation.
Future directions
The ready availability of the IDIPGR resources to external investigators has promoted 
robust, hypothesis-driven international and interdisciplinary collaborative research on all 
aspects of DIPG. Areas of focus for the IDIPGR are: to prospectively enrol patients 
diagnosed with DIPG, expand participation to other regions around the world, develop 
supplemental web-based educational materials for families and medical teams to improve 
awareness and treatment of DIPG. Ultimately, the IDIPGR’s extensive and robust 
infrastructure for collaborative research may serve as a platform to develop and conduct 
innovative, multi-institutional trials to improve the outcome for patients with DIPG.
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Fig. 1. 
Organizational of the DIPG registry and repository
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Table 1
Patient characteristics and available imaging, pathology and molecular data
Category Subcategory December 2016 n
Total enrollment 670
Collaborating institutions 55
Sex Female:male 351:319
Age at diagnosis (years) Mean age (range) 7.4 (<0.1 to 26.8 years)
Ethnicity African American 43
Asian 15
Caucasian 278
Other 11
Unknown 323
Neuroimaging 541 (3558 studies)
Diagnostic 448
MRI 3182 studies
CT 376 studies
Central review 438
  Not DIPG 29
  Typical DIPG 300
  Some atypical features 109
Biospecimens Targeted only
Central review 54
Autopsies coordinated 24
Fresh tissue shared for in vitro and
  in vivo modeling 7
Frozen 57
FFPE 19
Slides only 8
Molecular data 66
Whole exome 21
Whole genome 29
Targeted only 16
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